Authorised Phase II and Phase III (Integrated) Semantic Variant Primary Progressive Aphasia

CIRAANO: Multimodal exploration of theater actors, memory athletes, and patients with various memory pathologies: evaluation of mnesic strategies and their cerebral substrates, and contribution to the treatment of memory pathologies.

EU CTIS ID: 2025-523264-21-00

What this study is testing

[Part 2] to evaluate, in different categories of patients with memory disorders of various origins, the preservation or alteration of memory-related brain networks, associated with different types of memory strategies identified in memory experts.

Phase II and Phase III (Integrated)

A plain-language read of the study's public EU CTIS listing. The study team confirms the details.

Who can take part

You may be able to join if

[all participants] Minimum education level of 7 years (at least equivalent to the French Certificat d’Études Primaires (CEP))
[HC] Aged 18 or older
[HC] Neuropsychological performance within the normal range for age and education level on all inclusion battery tests (±1.65 standard deviation)
[HC] Be considered capable of complying with the protocol according to the investigator's judgment
[ATHL] Aged 18 or older
[ATHL] Must have participated in a memory competition—international, European, or national level

You likely can't join if

[all participants except informants] Pregnant or breastfeeding women
[all participants except informants] Presence of contraindications to MRI (e.g., claustrophobia, ferromagnetic objects in the body) or to Amyvid® and Tauvid® PET scans.
[SCD] Presence of depressive symptoms (MADRS score > 34, threshold for severe depression)
[MCI-AD] Presence of depressive symptoms (MADRS score > 34, threshold for severe depression)
[MCI-AD] Use of Alzheimer’s disease medications (including but not limited to donepezil, rivastigmine, galantamine, and memantine) at non-stabilized doses within 8 weeks prior to the inclusion visit
[D-AD, LBD & svPPA] Presence of depressive symptoms (MADRS score > 34, threshold for severe depression)

See the full eligibility criteria

Who can join

[all participants] Minimum education level of 7 years (at least equivalent to the French Certificat d’Études Primaires (CEP))
[HC] Aged 18 or older
[HC] Neuropsychological performance within the normal range for age and education level on all inclusion battery tests (±1.65 standard deviation)
[HC] Be considered capable of complying with the protocol according to the investigator's judgment
[ATHL] Aged 18 or older
[ATHL] Must have participated in a memory competition—international, European, or national level
[ATHL] Be considered capable of complying with the protocol according to the investigator's judgment
[SCD] Aged 60 or older
[SCD] Recruited from memory clinics
[SCD] Must meet recognized criteria for subjective cognitive decline in the context of the preclinical stage of Alzheimer’s disease
[MCI-AD] Aged 60 or older
[all participants] Native French speaker and educated in French
[MCI-AD] Recruited from memory clinics
[MCI-AD] Must meet current recognized clinical criteria for mild cognitive impairment due to Alzheimer’s disease
[D-AD] Aged 60 years or older
[D-AD] Recruited from memory clinics
[D-AD] Meeting current and recognized clinical criteria for major neurocognitive disorder due to probable Alzheimer’s disease
[LBD] Aged 60 years or older
[LBD] Recruited from memory clinics
[LBD] Meeting current and recognized clinical criteria for probable Lewy body dementia or probable prodromal Lewy body dementia (mild cognitive impairment with Lewy bodies)
[svPPA] Aged 50 years or older
[svPPA] Recruited from memory clinics
[all participants] Affiliated with a French social security scheme or beneficiary of such a scheme
[svPPA] Meeting current and recognized clinical criteria for semantic dementia
[AUD] Aged 18 years or older
[AUD] Recruited from an addiction treatment service
[AUD] Undergoing treatment primarily for an alcohol use disorder at the time of inclusion
[AUD] Detoxified, with withdrawal symptoms resolved (Cushman score <3, Cushman et al., 1985) and benzodiazepines discontinued at the time of inclusion
[AUD] Abstinent from all psychoactive substances (except tobacco and prescribed medication) at the time of inclusion
[AMN] Aged 18 years or older
[AMN] Recruited from hospital services or residential facilities housing patients with non-degenerative amnesic syndromes
[AMN] Presenting with major cognitive impairment : Characterized primarily by severe episodic memory deficits (anterograde amnesia), possibly associated with retrograde amnesia and/or other impairments ; Leading to significant impacts on daily functioning and reduced autonomy ; Persistent and stable over time
[NARCO] Aged 18 years or older
[all participants] Willingness to undergo several days of assessments
[NARCO] - Diagnosed with type 1 narcolepsy according to the 3rd edition of the International Classification of Sleep Disorders (ICSD-3), which includes daytime sleepiness persisting for more than 3 months, and either : Presence of cataplexy, mean sleep latency <8 minutes on the Multiple Sleep Latency Test (MSLT), and at least two REM sleep onsets (on MSLT and/or overnight polysomnography) ; Or cerebrospinal fluid hypocretin level <110 pg/mL.
[Informant] Aged 18 years or older
[Informant] Spending at least one day per week with a relative included in one of the patient groups
[all participants] Adherence to lifestyle considerations
[all participants] Signed informed consent to participate in the study
[ACT] Aged 18 or older
[ACT] Must have performed in at least one theatre play in the last three years
[ACT] Must be or have been a professional actor, either freelance or permanent (e.g., in a theatre company or at the Comédie-Française) for at least 5 years

What rules you out

[all participants except informants] Pregnant or breastfeeding women
[all participants except informants] Presence of contraindications to MRI (e.g., claustrophobia, ferromagnetic objects in the body) or to Amyvid® and Tauvid® PET scans.
[SCD] Presence of depressive symptoms (MADRS score > 34, threshold for severe depression)
[MCI-AD] Presence of depressive symptoms (MADRS score > 34, threshold for severe depression)
[MCI-AD] Use of Alzheimer’s disease medications (including but not limited to donepezil, rivastigmine, galantamine, and memantine) at non-stabilized doses within 8 weeks prior to the inclusion visit
[D-AD, LBD & svPPA] Presence of depressive symptoms (MADRS score > 34, threshold for severe depression)
[D-AD, LBD & svPPA] Absence of a caregiver or informant (i.e., a trusted person or relative who will be present from inclusion through the assessments, for patients with major cognitive impairment)
[D-AD, LBD & svPPA] Use of Alzheimer’s disease medications (including but not limited to donepezil, rivastigmine, galantamine, and memantine) and/or L-DOPA for LBD patients, at non-stabilized doses within 8 weeks prior to the inclusion visit
[D-AD, LBD & svPPA] Inability to understand instructions
[AUD & AMN] Presence of depressive symptoms (MADRS score > 34, threshold for severe depression)
[AUD & AMN] Evidence suggesting a probable neurodegenerative disorder (e.g., impairment in instrumental cognitive functions)
[all participants except informants] Chronic use of medications that affect cognition and/or may interfere with cognitive or imaging assessments (including non-tricyclic antidepressants, anticonvulsants such as lamotrigine, pregabalin, levetiracetam ; atypical antipsychotics; short-/intermediate-acting benzodiazepines such as alprazolam, lorazepam, oxazepam, temazepam; and sedative antihistamines), if doses were not stabilized within the 6 weeks prior to inclusion (except for changes due to withdrawal treatment in AUD patients)
[all participants except informants] Known hypersensitivity to Amyvid® or Tauvid®
[NARCO] Presence of depressive symptoms (MADRS score > 34, threshold for severe depression)
[all participants except informants] Participation in a clinical study involving exposure to ionizing radiation within the year prior to inclusion
[all participants except informants] Current participation in a clinical trial and/or other research involving human participants (RIPH) if it includes imaging examinations using radiotracers
[all participants except informants] History of neurological or neurosurgical conditions that could significantly affect cognitive function and/or neuroimaging (e.g., head trauma with loss of consciousness >30 minutes, stroke, multiple sclerosis, insulin coma)
[all participants except informants] Schizophrenia, psychotic disorders, or bipolar disorders (according to DSM-5 criteria)
[all participants except informants] Having a score suggesting an alcohol dependence (>9) on the FACE questionnaire (except for AUD patients)
[all participants except informants] Presence of untreated chronic or acute illnesses (respiratory, cardiovascular, gastrointestinal, renal, metabolic, hematologic, endocrine, or infectious)
[all participants except informants] Current use of long-acting benzodiazepines, typical antipsychotics, tricyclic antidepressants, or first-generation antihistamines at the time of inclusion (unless related to withdrawal treatment in AUD patients), with discontinuation of such medication less than 3 months prior to inclusion
[all participants except informants] Physical, behavioral, or geographical limitations preventing participation in the study
[all participants except informants] Refusal to cooperate during assessments
[HC] Current or recent (within the last 5 years) theater practice
[HC] Presence of depressive symptoms (MADRS score > 19, threshold for moderate depression)
[ACT & ATHL] Presence of depressive symptoms (MADRS score > 19, threshold for moderate depression)
[ACT & ATHL] Use of Alzheimer’s disease medications (including but not limited to donepezil, rivastigmine, galantamine, and memantine) at non-stabilized doses within 8 weeks prior to the inclusion visit

The study team makes the final eligibility decision.

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.

Explore other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH)Heart failure Coronary artery disease

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.